Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 5/5 | 4/5 |
| User rating | 4.5 (58) | 4.5 (76) |
| Typical dose | Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal | Determined individually by a doctor, usually 500–2000 mg daily in divided doses, with meals |
| Form | Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound) | Oral tablets, including extended-release (XR) forms that reduce gastrointestinal discomfort |
| Average price | ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki | — |
| Monthly cost | ok. 1000–1600 zł/miesiąc | — |
| Time to effects | Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment. | Lowering of glycemia is usually visible within days to weeks of starting therapy and reaching the target dose. |
| Who it's for | People with type 2 diabetes with inadequate glycemic control on other oral medications | People with type 2 diabetes or prediabetes, qualified by a doctor |